Managing HIV. Part 5: Treating secondary outcomes. 5.1 HIV and skin disease.
The skin is the largest and most visible organ of the body, and a perception of good health depends on its appearance as well as its function. As about 90% of HIV-infected patients develop cutaneous signs and symptoms, diagnosis and management are vital in recognising progression of HIV infection.
Wong
D
D
Shumack
S
S
D000212:Acyclovir / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D003881:Dermatomycoses / Q000209:etiology; D003875:Drug Eruptions; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000209:etiology; D012871:Skin Diseases / Q000188:drug therapy* / Q000209:etiology*; D017444:Skin Diseases, Papulosquamous / Q000209:etiology; D012878:Skin Neoplasms / Q000209:etiology
D000935:Antifungal Agents; D000998:Antiviral Agents; D007654:Ketoconazole; D000212:Acyclovir